In our attempt to seek novel strategy to treat pancreatic cancer, we found that VPA exhibits a promising anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer. This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.